Replies to post #580 on Outlook Therapeutics Inc (OTLK)

[H2R]

Pricing Space from latest Presentation:



The $500-$1000 space is wide open.

See VMLG17's post

"Vabysmo reduced dosing even further, to once every four months. Its annual list price of $6,570 during that maintenance phase, or $2,190 a shot, is competitive with Lucentis biosimilars, which cost around $1,000 a shot. Eylea biosimilars are expected to enter sometime this year or next."

Best of luck with your investments!